News

News and Comment

  • 09 December 2016

    Acting on the potential of action potentials: will bioelectronic medicines be the next biologics?

    Read more
  • 01 August 2016

    GSK and Verily to establish Galvani Bioelectronics – a new company dedicated to the development of bioelectronic medicines

    Read more
  • 11 March 2015

    GlaxoSmithKline's big bet on electroceuticals

    Read more
  • 30 June 2014

    Shock Therapy: the nascent bioelectronic medicine field will require a multidisciplinary effort to succeed

    Read more
  • 30 May 2014

    Bioelectronic medicines: a research roadmap

    Read more
  • 23 May 2014

    Can the Nervous System be Hacked?

    Read more
  • 08 August 2013

    GSK launches venture capital fund to invest in pioneering bioelectronic medicines and technologies

    Read more
  • 10 April 2013

    Drug discovery: A jump-start for electroceuticals

    Read more

Portfolio News

  • CVRx secures $113 Million in new financing. Equity offering to support heart failure trial was oversubscribed

    Read more

    09 August 2016

  • SetPoint's breakthrough first-in-human study shows vagus nerve stimulation significantly reduces rheumatoid arthritis symptoms, inhibits cytokine production

    Read more

    04 July 2016

  • SetPoint announces $15 Million equity financing, adds major strategic investor. Series C1 funding supports ongoing development of bioelectronic therapies

    Read more

    08 September 2015

  • SetPoint announces first trial of Bioelectronic therapy to treat Crohn's Disease. Second study in humans to evaluate bioelectronic medicine for autoimmune disease.

    Read more

    04 December 2014

  • SetPoint Medical Named One of the “Fierce 15” Leading Medical Technology Companies of 2013

    Read more

    15 October 2013

  • SetPoint Medical Secures $27 Million Financing, Adding Action Potential Venture Capital/GSK, Boston Scientific and Covidien Ventures as New Investors

    Read more

    08 August 2013